DISTILLATION №74 — REFINED

[Asp2]Semax · MC4R Selectivity Probe

Sequence: MDHFPGP (Glu-2 → Asp) | Target: MC4R (UniProt P32245) | Class: Cognitive

Mechanism of Action

Semax is structurally derived from ACTH(4-10), and ACTH signals through all five melanocortin receptors (MC1R–MC5R). The His-Phe dipeptide at positions 3-4 constitutes the minimal pharmacophore for melanocortin receptor engagement — a β-turn motif that inserts into the extracellular vestibule and makes hydrophobic and electrostatic contacts with conserved receptor residues. The N-terminal Met-Glu segment of Semax is believed to contribute an electrostatic anchoring interaction with a basic residue (Arg or Lys) presented at the TM2/ECL1 interface, a contact geometry that differs subtly across receptor subtypes due to differences in the depth and identity of the partnering residue.

Importantly, the CNS effects of Semax documented in the literature — BDNF/NGF upregulation, monoaminergic modulation, anti-inflammatory cytokine regulation, and copper chelation — are likely pleiotropic and not exclusively MCR-mediated. Liu et al. (2025) identify opioid/USP18 pathways in spinal cord injury contexts; Medvedeva et al. (2017) document immune/interferon signaling; and the Eremin et al. (2005) paper explicitly links melanocortinergic and monoaminergic systems in the context of Semax's striatal serotonergic effects. Any selectivity engineering at the receptor level must be interpreted against this multi-mechanistic backdrop.

Performance Applications

MC4R is a therapeutically validated target for metabolic regulation (appetite suppression, energy expenditure) and has been implicated in cognitive and neuroprotective signaling, mood regulation, and erectile function. Enhanced MC4R selectivity over MC1R is desirable for two reasons: (1) MC1R activation drives melanogenesis and pigmentation effects — an unwanted side effect for a cognitive/neuroprotective agent; (2) MC5R activation is associated with sebaceous gland stimulation. A Semax analogue with improved MC4R/MC1R selectivity ratio could, in principle, preserve or enhance the nootropic and neuroprotective profile while reducing dermatological off-target activity.

In the biohacker and research-use context, this makes [Asp2]Semax an interesting selectivity probe — not a dose-escalation or stability play, but a subtype-discrimination experiment. If wet-lab validation confirmed improved MC4R/MC1R selectivity, it would also open the door to metabolic and appetite-regulatory applications that are pharmacologically distinct from native Semax's established neuroprotective profile.

Modification Rationale

The Glu-2 → Asp substitution is the simplest possible acidic-side-chain truncation: it removes one methylene group (~1.5 Å), preserving the negative charge and hydrogen-bonding donor/acceptor profile while reducing side-chain reach. The logic is geometric: if the basic residue at the MC4R TM2/ECL1 rim sits shallower in the binding vestibule than the corresponding residue in MC1R (as suggested by comparative receptor homology analysis), then a shorter carboxylate would achieve optimal salt-bridge geometry at MC4R while losing contact efficiency at MC1R. This is a well-established medicinal chemistry strategy in GPCR peptide SAR — the MT-II/MS05 melanocortin analogue series, for example, demonstrates that single-atom changes in the acidic recognition element can shift subtype selectivity by orders of magnitude.

This modification is meaningfully distinct from all prior Semax folds in this lab. Fold #1 (N-terminal acetylation) modified the Met-1 α-amino group — abolishing the positive charge at the terminus, a change orthogonal to the Glu-2 carboxylate geometry. Fold #49 (His-3 methylation) targeted the imidazole tautomer to optimize aromatic stacking at the receptor. Fold #61 (Pro-5 → Hyp) rigidified the central β-turn via stereoelectronic effects. Fold #55 (cyclization) constrained the global topology. None of these touched Glu-2, leaving the position-2 SAR point entirely unexplored until now.

The Glu-2 residue is also a participant in the Met-Glu-His Cu(II) chelation complex characterized by Sciacca et al. (2022) and Tomasello et al. (2025). Shortening this residue will alter the chelation geometry — a meaningful confound for in vivo or cell-based selectivity assays (discussed under limitations).

Predicted Properties (Favourable Changes from Native)

All values are in silico predictions or heuristic estimates. Selectivity improvement is a geometric inference from the predicted binding pose — no quantitative ΔΔG or MC1R counter-screen was computed.

The structural prediction places the Asp-2 carboxylate in proximity to a basic residue at the MC4R TM2/ECL2 rim, consistent with the hypothesized tighter salt-bridge. The His-Phe pharmacophore core is fully preserved, suggesting the substitution does not disrupt the primary receptor-recognition element. The near-zero aggregation propensity is an improvement over many modified peptides and suggests the variant should be synthetically tractable and solution-stable.

Suggested Next Steps

Further variants to consider:

• [β-Asp2]Semax — replace Glu-2 with beta-aspartic acid (an isomer with an extended backbone connectivity) to probe whether the backbone geometry matters as much as the side-chain length at position 2.
• [Gln2]Semax — neutral amide isostere of Glu-2 as a negative control; if selectivity shifts disappear, this confirms the electrostatic mechanism.
• [D-Asp2]Semax — D-amino acid at position 2 would also disrupt the Cu(II) chelation triad and provide a stereochemical probe of the salt-bridge geometry; compare with Fold #41 (D-Thr-1 Selank), which earned a PROMISING verdict on a related design logic in the same lab series.
• Counter-screen fold: [Asp2]Semax vs. MC1R — a computational fold docking the same MDHFPGP sequence against MC1R (UniProt Q01726) would provide the selectivity ratio inference that this fold alone cannot deliver. This is the highest-priority next computational step.

Validation experiments:

• Radioligand displacement assay — competitive binding of [Asp2]Semax vs. [125I]-NDP-α-MSH at hMC4R and hMC1R expressed in HEK293 cells; this is the definitive selectivity readout and would establish Ki values at both subtypes.
• cAMP functional assay (Gs) — measure EC50 and Emax at MC4R and MC1R in parallel to capture any functional selectivity (biased agonism) not captured by binding alone.
• Cu(II) chelation titration — ITC or UV-vis spectroscopic titration of [Asp2]Semax with Cu(II) vs. native Semax to quantify the Kd shift introduced by the Glu→Asp change; this would allow the copper confound to be characterized and controlled for in cellular assays.
• SPR binding kinetics — surface plasmon resonance on immobilized MC4R ECD (or nanodisc-reconstituted receptor) to compare kon/koff for native vs. [Asp2]Semax and estimate whether the interface improvement predicted by ipTM translates to slower off-rate.
• NMR structural characterization — 2D NOESY in aqueous solution to confirm that the His-Phe β-turn geometry is maintained in [Asp2]Semax and that the Asp-2 side chain adopts a conformation compatible with the predicted salt-bridge geometry.

Cross-fold integration: This fold complements the emerging Semax SAR map in this lab. The combination of Fold #49 (His-3 methylation, optimizing the aromatic stacking interaction) with Fold #74's Asp-2 substitution (optimizing the electrostatic anchor) represents a logical double-substitution candidate — [D-mHis3, Asp2]Semax — that could be explored in a future fold to assess whether the two modifications are additive or interfering at the receptor interface.